Is it advisable to invest in Pfizer's stock at present?
=========================================================================
In the first quarter of this year, Pfizer spent $4.2 billion on dividends and share repurchases, reflecting the company's strong financial position. However, the question remains: is Pfizer a worthwhile investment in 2022?
Over the past decade, investors have often paid more for Pfizer's stock, and the company currently offers a dividend that yields 3.1%, which is more than double the rate of the average S&P 500 stock. This attractive dividend, coupled with the company's significant cash reserves accumulated from its COVID-19 products, could make Pfizer an appealing choice for income-focused investors.
However, the current market value of Pfizer's stock suggests that investors are not willing to pay a significant premium for the company, possibly due to concerns about the long-term sustainability of its COVID-19 revenue. The demand for Pfizer's COVID-19 vaccines and pills could potentially drop as concerns about COVID-19 subside, according to an Ipsos poll.
Despite this, Pfizer's business isn't solely dependent on COVID-19 products. In a recent quarter, the company generated close to $50 billion in sales from its other products, and it has made multiple acquisitions in the healthcare industry over the past year, including Biohaven Pharmaceuticals, ReViral, and Arena Pharmaceuticals. These acquisitions expand Pfizer's pipeline and set the company up for potential better growth prospects.
The Food and Drug Administration has recently granted Emergency Use Authorization for Pfizer's vaccine for children between the ages of six months to four years, which could further boost its revenue from COVID-19 products. Pfizer's COVID-19 revenue could continue due to the need for booster shots and managing long COVID.
Evaluating Pfizer stock in 2022, given its COVID-19 revenue and recent acquisitions, requires considering Pfizer’s strong revenue from COVID-19 products at that time and the outlook beyond pandemic-related sales. In 2022 specifically, Pfizer shares likely reflected both strong COVID-19-related cash flows and uncertainties about how revenue would evolve after the pandemic peak. Buying then would depend on your risk tolerance: investors seeking exposure to near-term COVID revenues and vaccine momentum might have found a favorable opportunity, but those concerned about patent cliffs and post-pandemic growth might have been more cautious.
By 2025, Pfizer's revenue growth rates have moderated, but the company is still expected to generate substantial earnings, indicating recovery and growth beyond the pandemic peak. Analysts in 2025 generally rate Pfizer as a "Hold," with a price target roughly 27% above current prices, reflecting cautious optimism but concerns like patent cliffs yet to be fully addressed.
In conclusion, Pfizer stock in 2022 was a mixed proposition—strong COVID-19 revenue provided a temporary boost, yet investors needed to weigh that against medium-term growth challenges and the evolving impact of acquisitions aimed at diversification. By 2025, this balance results in a "Hold" consensus rather than a strong buy recommendation. Whether Pfizer is worth buying today remains a decision for each investor to make based on their individual risk tolerance and investment goals.
Engaging in investing, one might consider Pfizer as a potential opportunity due to its attractive dividend and substantial cash reserves. However, the market value of Pfizer's stock suggests that money might be tight for those seeking significant returns, as investors may be hesitant due to concerns about the long-term sustainability of its COVID-19 revenue.
